September 17, 2000Open Access

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

Key Points

Key points are not available for this paper at this time.

Abstract

GC provides a similar survival advantage to MVAC with a better safety profile and tolerability. This better-risk benefit ratio should change the standard of care for patients with locally advanced and metastatic TCC from MVAC to GC.

Read Full Paperexternally

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Maase et al. (Sun,) studied this question.

synapsesocial.com/papers/69d9845c5e5bcb4e3b836e80 https://doi.org/https://doi.org/10.1200/jco.2000.18.17.3068

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial1999 · 154 citations
2Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer2000 · 262 citations
3Gemcitabine in locally advanced and/or metastatic bladder cancer2000 · 14 citations
4Gemcitabine Plus Cisplatin, an Active Regimen in Advanced Urothelial Cancer: A Phase II Trial of the National Cancer Institute of Canada Clinical Trials Group1999 · 230 citations
5M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the Urothelium1988 · 628 citations

AI에게 질문

Bookmark

View Full Paper